Patents by Inventor J. Allen D. Cooper, Jr.

J. Allen D. Cooper, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and methods for the inhibition of phagocytes
    Patent number: 6017883
    Abstract: The present invention relates to the identification, purification and characterization of novel factors which inhibit phagocyte activation, such as inhibiting polymorphonuclear neutrophil chemotaxis, degranulation and superoxide production. Disclosed are natural peptides purified from the bronchial environment and a variety synthetic peptides and analogues designed to have enhanced or longer-lasting phagocyte-inhibiting activity. The peptides and compositions of the present invention are contemplated for use in modulating inflammatory responses in a number of clinical settings, such as in the treatment of asthma, bronchitis, acute lung injury, rheumatoid arthritis, psoriasis, dermatitis and inflammatory bowel disease, and for use as anti-proliferative agents such as in the treatment of cancer.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: January 25, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: J. Allen D. Cooper, Jr.
  • Compositions and methods for the inhibition of phagocytes
    Patent number: 5861475
    Abstract: The present invention relates to the identification, purification and characterization of novel factors which inhibit phagocyte activation, such as inhibiting polymorphonuclear neutrophil chemotaxis, degranulation and superoxide production. Disclosed are natural peptides purified from the bronchial environment and a variety synthetic peptides and analogues designed to have enhanced or longer-lasting phagocyte-inhibiting activity. The peptides and compositions of the present invention are contemplated for use in modulating inflammatory responses in a number of clinical settings, such as in the treatment of asthma, bronchitis, acute lung injury, rheumatoid arthritis, psoriasis, dermatitis and inflammatory bowel disease, and for use as anti-proliferative agents such as in the treatment of cancer.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: January 19, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventor: J. Allen D. Cooper, Jr.